This study aims to systematically evaluate the efficacy of mindfulness-based intervention (MBI) in improving mental health and quality of life for people with dementia. Comprehensive literature search was performed using the PubMed, EMBASE, Web of Science, Cochrane Library, and CINAHL databases from their inception till June 26, 2019. In total, nine articles met the eligibility criteria and were included. The results of the meta-analysis showed a statistically significant decrease in depressive symptoms (SMD = −0.39, 95% CI: − 0.62 to − 0.15), in people with dementia who were treated with MBI. However, there were no significant improvements in anxiety, stress, or quality of life. These findings suggest that MBI is a promising alternative to conventional interventions in the treatment of depression among dementia patients and warrant further study.

Background Lipoprotein (a) is a determined causal risk factor for residual risks of recurrent ischemic cardiovascular events. Alirocumab has been found to reduce lipoprotein (a) levels. However, its effects on lipoprotein (a) and inflammation marker in a Chinese population with unstable angina remain to be characterized. Aim We aimed to assess the effect of alirocumab on lipoprotein (a) and inflammatory marker in Chinese subjects with unstable angina. Method In a retrospective before-after study, lipoprotein (a), interleukin-6 and other lipid profiles were measured before and after 4 weeks of alirocumab treatment in 53 patients with unstable angina (UA) who had already received oral lipid-lowering therapies. Results The alirocumab significantly lowered the levels of lipoprotein (a) (−11.28 mg/dL; p< 0.001) and interleukin-6 (-1.65 pg/mL; p < 0.001) after treatment. Moreover, there was a positive linear correlation between lipoprotein (a) and interleukin-6 at baseline (R=0.86; p < 0.001). Furthermore, in 11 patients with lipoprotein (a) levels ≥ 50 mg/dL at baseline, lipoprotein (a) (-27.37 mg/dL; p < 0.001) and interleukin-6 (-2.97 pg/mL; p < 0.001) decreased after treatment. In 42 patients with lipoprotein (a) levels < 50 mg/dL at baseline, lipoprotein (a) (-7.07 mg/dL; p = 0.001) and interleukin-6 (-1.31pg/mL, p < 0.001) also decreased after treatment. Conclusions Early application of alirocumab may be effective in reducing the levels of lipoprotein (a) and interleukin-6 in Chinese patients with unstable angina in the short term, especially in patients with lipoprotein (a) ≥ 50 mg/dL.